Multiple Myeloma

Jesus Berdeja, MD, discusses updated results from the ongoing phase 1b/2 CARTITUDE-1 trial (NCT03548207) in multiple myeloma.

When added to bortezomib and dexamethasone in patients with multiple myeloma, selinexor, an inhibitor of XPO1-mediated nuclear export, improves progression-free survival and overall response rate and reduces the incidence of peripheral neuropathy.

Belantamab mafodotin in combination with bortezomib (Velcade) and dexamethasone (B-Vd) demonstrated a high rate of clinical benefit and an acceptable safety profile in patients with relapsed or refractory multiple myeloma.

Single agent belantamab mafodotin sustained clinically meaningful deep responses and was well tolerated in patients with heavily pretreated relapsed or refractory multiple myeloma.

Nikhil C. Munshi, MD, discusses the role of CAR T-cell therapy in relapsed/refractory multiple myeloma.

Sagar Lonial, MD, FACP, discusses the results of the phase 2 DREAMM-2 trial in multiple myeloma.

The combination of next-generation proteasome inhibitor carfilzomib, lenalidomide, and dexamethasone did not show a superiority in progression-free survival in patients with newly diagnosed multiple myeloma when compared with the current standard of care triplet of bortezomib, lenalidomide and dexamethasone.

Betsy O'Donnell, MD, discusses transplant considerations in patients with multiple myeloma.

Andrew Branagan, MD, discusses the role of autologous stem cell transplantation in patients with high-risk multiple myeloma.

Gareth J. Morgan, MD, PhD, provides insight on determining treatment selection for patients with multiple myeloma.

In our exclusive interview, Maria-Victoria Mateos, MD, PhD, discusses the FDA approval of the subcutaneous daratumumab formulation in multiple myeloma.

Andrew Yee, MD, discusses the phase 3 CANDOR trial in relapsed/refractory multiple myeloma.

A supplemental New Drug Application has been submitted to the FDA for the use of selinexor as a treatment for patients with multiple myeloma following at least 1 line of prior therapy.

A supplemental New Drug Application has been submitted to the FDA for the use of selinexor as a treatment for patients with multiple myeloma following at least 1 line of prior therapy.

Peter Voorhees, MD, discusses the benefit of monoclonal antibodies in multiple myeloma.

Nizar J. Bahlis, MD, discusses updated data from the phase 3 MAIA trial in multiple myeloma.

Peter Voorhees, MD, discusses the benefit of monoclonal antibodies in multiple myeloma.

Betsy O'Donnell, MD, discusses the utility of up-front triplet regimens in multiple myeloma.

Maria-Victoria Mateos, MD, PhD, discusses the data that led to the approval of the subcutaneous daratumumab formulation and the clinical implications of the regulatory decision.

The FDA has issued a Refusal to File letter to Bristol Myers Squibb and bluebird bio, Inc., regarding their Biologics License Application (BLA) for the BCMA-directed CAR T-cell therapy decabtagene vicleucel.

The FDA has requested additional details before accepting a biologics license application for idecabtagene vicleucel for the treatment of patients with multiple myeloma.

Maria-Victoria Mateos, MD, PhD, discusses the data that led to the approval of the subcutaneous daratumumab formulation and the clinical implications of the regulatory decision.

Marc J. Braunstein, MD, PhD, discusses updated results from the GRIFFIN trial in multiple myeloma.